ÐÂÎÅ×ÊѶ
ÕãÒ½¶ùÔºÍŶÓ×îÐÂ×êÑгɾͣºÊ¯É¼¼î¼×ÓÐÍûÒ½ÖÎÌÇÄò²¡Éö²¡
ÈÕÆÚ£º
2024Äê10ÔÂ26ÈÕ 08:51
½üÆÚ£¬ÓÉÕã½´óѧҽѧԺ´ÓÊô¶ùͯҽԺÉöÄÚ¿ÆÍŶÓÓëJ9¼¯ÍźÏ×÷·¢Õ¹µÄʯɼ¼î¼×Ò½ÖÎÌÇÄò²¡Éö²¡µÄ¶à×éѧ·ÖÎö×êÑа䷢ÁË×îÐÂ×êÑÐÁ˾֣¬×êÑн²ÁËȻʯɼ¼î¼×Ô¿äõÇáÌÇÄò²¡ÓÕµ¼µÄÉöΣÏÕ¡¢Ö¬ÖÊ´úл´íÂÒºÍÑ×Ö¢·½ÃæÏÔʾ³öÓе«Ô¸µÄÒ½Öι¦Ð§¡£¸Ã×êÑÐÒѰ䷢ÓÚ¡¶Pharmacological Research¡·ÔÓÖ¾£¬È«ÃûΪ“Huperzine A targets Apolipoprotein E: A potential therapeutic drug for diabetic nephropathy based on omics analysis”¡£
ÔçÔÚ2020Ä꣬Õã½´óѧҽѧԺ´ÓÊô¶ùͯҽԺ¾ÍÓëJ9¼¯ÍźÏ×÷·¢Õ¹¹ýÑÎËáä强ÐÂÆ¬¶Ô¶ùͯÐÂÐ͹Ú×´²¡¶¾Ï°È¾µÄÁÆÐ§¼°°²È«ÐÔÆÀ¼Û×êÑС£Èç½ñÔÙ´ÎÁªÊÖ£¬ÓÖÔÚÐµļ²²¡ÁìÓò»ñµÃÁËϲÈ˵ijɾ͡£
ʯɼ¼î¼×£ºÌìÈ»·îË͵ĶàÃæÄÜÊÖ
ʯɼ¼î¼×(Huperzine A£¬Hup A)×÷ΪÑÇÖÞÖ²ÎïÉß×ãʯɼµÄÌáÈ¡ÎïÁÙ´²ÖØÒªÓÃÓÚÉñ¾ÍËÐÐÐÔ²¡Ò½ÖΣ¬µ«½üÄêÀ´×êÑз¢ÏÔìäÔÚÌÇÄò²¡ÊÓÍøÄ¤²¡±äÖÐÓµÓÐÏÔÖøµÄ½µÑªÌǺͿ¹Ñ××÷Óᣵ«Æä¸ü¿í·ºµÄ±£»¤×÷Ó㬳ö¸ñÊǶÔÌÇÄò²¡ÁíÒ»²¢·¢Ö¢ÌÇÄò²¡Éö²¡ÉöÖ°Äܵı£»¤×÷ÓÃÈÔδ±»×êÑС£
ÌÇÄò²¡Éö²¡£ºÇÄÈ»Âñ·üµÄ½¡È«É±ÊÖ
ÌÇÄò²¡£¨DM£©×÷Ϊ³£¼û²¡¡¢¶à·¢²¡£¬ÊÇÑϳÁÍþвÈËÀཡȫµÄÊÀ½çÐÔ¹«¹²ÎÀÉúÎÊÌ⡣ĿǰÔÚÊÀ½çÁìÓòÄÚ£¬ÌÇÄò²¡»¼²¡Âʺͻ¼²¡ÈËÊý¼±¾çÉÏÉý£¬¾Ý¹ú¼ÊÌÇÄò²¡Í¬ÃË£¨IDF£©Í³¼Æ£º2021ÄêÈ«Çò³ÉÄêÌÇÄò²¡ÈËÊýÒÑ´ï5.37ÒÚ£¬½Ï2019ÄêÔö³¤½ü16%£¬Ô¤¼Æµ½2045ÄêÈ«ÇòÌÇÄò²¡»¼²¡×ÜÈËÊý½«´ïµ½7.83ÒÚ£»2021ÄêÈ«ÇòÒòÌÇÄò²¡éæÃüÈËÊý´ï670Íò¡£
½ü40¶àÄêÀ´£¬Ëæ×ÅÎÒ¹ú¾¼Ã¸ß¿ì·¢Õ¹¡¢ÉúÑÄ·½Ê½Î÷·½»¯¡¢³ÇÊл¯ºÍÈ˶¡ÀÏÁ仯¡¢·ÊÅÖÂÊÉÏÉý£¬ÎÒ¹úÌÇÄò²¡»¼²¡ÂÊÒ²³Ê¼±¾çÔö³¤Ç÷Ïò£º1980ÄêÎÒ¹ú³ÉÈËÌÇÄò²¡»¼²¡ÂÊΪ0.67%£¬2007 Äê´ï9.7%£¬2017Äê¸ü¸ß´ï 11.7%¡£ÌÇÄò²¡Ç°ÆÚµÄ±ÈÀý¸ü¸ß¡£¸üΪÑϳÁµÄÊÇÎÒ¹úÔ¼ÓÐ50%µÄÌÇÄò²¡Î´±»Õï¶Ï£»¶øÒѽÓÊÜÒ½ÖÎÕߣ¬ÌÇÄò²¡½ÚÔìÇé¿öÒ²²»ÃÎÏë¡£IDFÊý¾ÝÏÔʾ£¬½ØÖÁ2021ÄêÎÒ¹ú³ÉÈËÌÇÄò²¡ÊýÁ¿Îª1.41ÒÚ¡£ÎÒ¹úÒÑÈ»³ÉΪȫÊÀ½çÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¶È¡£
¶øÌÇÄò²¡Éö²¡(diabetic nephropathy£¬DN)ÊÇÌÇÄò²¡×î³ÁÒªÇÒ×îÑϳÁµÄ²¢·¢Ö¢Ö®Ò»£¬·¢²¡»úÔ츴ÔÓ£¬Éæ¼°Ñõ»¯Ó¦¼¤¡¢Ñ×Ö¢¡¢ÏËά»¯ºÍϸ°ûµòÍö£¬ÁÙ´²ÌصãΪ³ÖÐøÐÔ°×µ°°×ÄòÉø³öÔö³¤£¬ÉöÓ×ÇòÂ˹ýÂÊ£¨eGFR£©½øÐÐÐÔ½µÂ䣬×îÖÕ·¢Õ¹ÎªÖÕÄ©ÆÚÉö²¡£¨ESRD£©£¬½ìʱÉöÔàÖ°Äܸù»ùʧÂ䣬ÑݱäΪÉöË¥½ß£¬ÌåÄÚ³öÏÖ´óÁ¿¶¾ËØ»ý´¢£¬Ë®¡¢µç½âÖÊ¡¢Ëá¼îʧºâ£¬ÖÂËÀÂʸߣ¬¼«¶ÈΣÏÕ¡£
¶ÔÓÚÌÇÄò²¡Éö²¡£¬Ä¿Ç°µÄÁÙ´²Ò½ÖÎÈÔÒÔÔçÆÚ½ÚÔìѪÌÇ¡¢ÑªÑ¹ÎªÖ÷£¬½øÐÐÖÁÍíÆÚÔò±ØÒªÑ¡È¡Í¸ÎöµÈÉöÔà´úÌæÁÆ·¨½øÐÐÒ½ÖΡ£ÉÐÎÞÓÐЧµÄÒ©Îï¹ýÎʼ¿Á©¡£
¶à×éѧ·ÖÎö£º½Òʾʯɼ¼î¼×µÄ×÷ÓûúÔì
±¾´Î×êÑÐÖУ¬×êÑÐÈËԱѡȡÁËת¼×é¡¢´úл×顢΢ÉúÎï×éºÍÍøÂçÒ©ÀíѧµÈ¶à×é±ð¶àѧ¿Æ×ۺϷÖÎö²½Ö裬̽Ë÷ÁËʯɼ¼î¼×¶ÔÓÚÌÇÄò²¡Éö²¡µÄÒ½ÖÎ×÷Óá£×êÑÐÁ˾ÖÏÔʾ£¬Ê¯É¼¼î¼×¿ÉÄÜͨ¹ýµ÷¿ØApoEµÄ±í°×£¬Æðµ½±£»¤ÉöÔà¡¢µ÷½Ú´úл¡¢¸ÄÉÆ³¦Â·Î¢ÉúÎïȺ¡¢¸ÄÉÆÑ×Ö¢µÈ×÷Ó᣸Ã×êÑгõ´ÎÌṩÁËʯɼ¼î¼×¶ÔDNÒ½ÖÎ×÷ÓõÄÖ¤¾Ý£¬Åúעʯɼ¼î¼×¿ÉÄÜͨ¹ý°ÐÏòµ÷¿ØApoE£¬³ÉΪһÖÖDZÔÚµÄÔ¤·ÀºÍÒ½ÖÎDNµÄÒ©Îï¡£¾ßÌåÈçÏ£º
1. ÉöÔà±£»¤×÷ÓãºÔÚÁÙ´²ÖУ¬Äòµ°°×ÊÇÆÀ¹ÀÉöÖ°ÄܺÍΣÏÕ¡¢ÌáÐÑÉöÔ༲²¡µÄ³ÁÒªÖ¸±ê¡£×êÑÐÅú×¢£¬ÔÚÐÛÐÔSD´óÊó¸øÒ©Ê¯É¼¼î¼×ºó£¬Óë¶ÔÕÕµÄδʹÓÃʯɼ¼î¼×µÄDN´óÊóÏà±È£¬Ê¹ÓÃÁËʯɼ¼î¼×µÄDN´óÊóÄòµ°°×£¨uALB£©Ë®Æ½³öÏÖ½µµÍ£¬²¢ÇÒÆäÉöÔàÖ¸Êý£¨kidney index£©¡¢Ñª¼¡ôû£¨SCr£©¡¢ÄòËØµª£¨BUN£©Ë®Æ½½ÔÓиÄÉÆ¡££¨ÈçÏÂͼ£©
£¨×¢£ºNCΪÕý³£´óÊó£»DNΪ»¼DN´óÊó£»DN+Hup AΪʹÓÃÊÇʯɼ¼î¼×µÄDN´óÊó¡££©


Áí±í£¬´óÊóÉöÓ×Çò£¨Glomerulus£©ºÍÉöÓ׹ܣ¨Renal tubule£©µÄ½á¹¹Î£ÏÕÔÚʯɼ¼î¼×Ò½ÖÎÏÂÒ²ÓÐËù¼õÇᣬά³ÖÕý³£ÉöÓ×ÇòÂ˹ýÖ°ÄÜËù±ØÐëµÄÉö²¡µ°°×£¨Nephrin£©ºÍ×ãÍ»µ°°×£¨Podocin£©µÄµ°°×ÖÊˮƽÔÚʯɼ¼î¼×¸øÒ©ºóÒ²ÏÔÖø»ØÉý¡£
¶ÔÕÕδÓÃÒ©µÄDN´óÊó£¬Ê¹ÓÃʯɼ¼î¼×ºóµÄ´óÊóÉöÔàÖ°ÄÜÖ¸±êÒÔ¼°½á¹¹Î£ÏÕÔÚʹÓÃʯɼ¼î¼×ºó¸ù»ù¶¼ÓÐËù¸ÄÉÆ¡£Òò¶øÄܹ»µÃ³ö£¬Ê¯É¼¼î¼×´æÔÚ×ŶÔÉöÔàµÄ±£»¤×÷Óá£
2. »ùÒò±í°×Ó°Ï죺ΪÁËË÷Çóʯɼ¼î¼×Ò½ÖÎDNµÄ·Ö×Ó»úÔ죬×êÑжÔÉöÔà×éÖ¯½øÐÐÁËת¼×é²âÐòºÍ²î¾à±í°×»ùÒò(DEG)·ÖÎö¡£Á˾ÖÏÔʾ£¬ÔÚDN×éÖÐÏÔÖøÉϵ÷µÄApoEºÍApoC 2ÔÚʯɼ¼î¼×Ò½ÖκóÏÔÖø½µµÍ¡£
3. ´úлÎïµ÷½Ú£º×êÑÐͨ¹ýÖ÷³É·Ö·ÖÎö£¨PCA£©ºÍÆ«×îÓ×¶þ³ËÅжϷÖÎö£¨PLS-DA£©À´×êÑÐÉöÔà´úл±ä¶¯·¢ÏÖ£¬NC×éºÍDN×éµÄÑùÆ·ÓµÓÐÏÔ×Å·ÖÉ¢ÐÔ£¬¶øDN+Hup AµÄÉ¢²¼¸ü¿¿½üNC×é¡£ÕâÒ²¾ÍÒâζ×Å£¬Ê¹ÓÃÁËʯɼ¼î¼×µÄDN´óÊóµÄÉöÔà´úлÏà±Å×ÚδÓÃÒ©µÄDN´óÊ󣬯äÉöÔà´úлԽ·¢¿¿½üÓÚÕý³£´óÊó¡£ÕâÅúעʯɼ¼î¼×Ò½Öο϶¨Ë®Æ½Éϸ´ÔÁËDN´óÊóµÄ´úл¡££¨ÈçÏÂͼ£©

4. ³¦Â·Î¢ÉúÎïȺ¸ÄÉÆ£ºShannonÖ¸ÊýÊÇÆÀ¹À΢ÉúÎïȺÂä¶àÑùÐÔ»ò·á˶¶ÈµÄ³£ÓÃÖ¸±ê£¬ÊýÖµÔ½¸ßÅúעȺÂäµÄ¶àÑùÐÔÔ½¸ß£¬¹Ê×êÑÐÓÃÆäÀ´ÆÀ¹Àʯɼ¼î¼×¶Ô´óÊó³¦Â·Î¢ÉúÎïȺµÄÓ°Ïì¡£Á˾ÖÏÔʾ£¬DN×éµÄShannon¶àÑùÐÔÖ¸Êý½µµÍ£¬¶øDN+Hup A×éµÄShannon¶àÑùÐÔÖ¸ÊýÔö³¤£¬Åúעʯɼ¼î¼×´¦Öõ÷½ÚÁË´óÊó³¦Â·Î¢ÉúÎïȺ¶àÑùÐÔ¡££¨ÈçÏÂͼ£©

ÁÙ´²Òâ˼£ºApoE×÷ΪÉúÎï±êÖ¾Îï
Ϊ̽Ë÷ApoEÓëDNÓйØÉúÎï±êÖ¾ÎïµÄÁÙ´²ÓйØÐÔ£¬×êÑÐÄÉÈëÁË428ÀýDN»¼Õß½øÇ°½øÒ»²½·ÖÎö¡£
ÌÇ»¯Ñªºìµ°°×£¨HbA1c£©ÊÇѪÌǽÚÔìˮƽµÄ³ÁÒªÖ¸±ê£¬Í¨³£ÒÔΪ£¬ÌÇ»¯Ñªºìµ°°×Ũ¶È¿ÉÓÐЧµØ·´Ó³´Óǰ8~12ÖܾùÔÈѪÌÇˮƽ¡£×êÑз¢ÏÖ£¬HbA1cÓëApoE³ÊÕýÓйأ¬ÌáÐÑApoEµÄ±í°×ËæHbA1cˮƽµÄÉý¸ß¶øÔö³¤¡£
ÔÚÉöÖ°ÄÜ·½Ã棬Ôڸߵ°°×ÄòˮƽÏ£¬ApoE±í°×Óë24 hÄòµ°°×ˮƽ³ÊÇ¿ÕýÓйأ¬Åú×¢Ëæ×ŵ°°×ÄòˮƽµÄÉý¸ß£¬ApoE±í°×Ò²Éý¸ß¡£
Áí±í£¬×êÑл¹·¢ÏÖ£¬ApoEÓëѪÇå°×µ°°×£¨ALB£©¡¢Ö¬ÖÊÉúÎï±êÖ¾Îï¡¢Ñ×Ö¢±êÖ¾ÎÓÈÆäÊÇCRPºÍHsCRP£©µÈ¶¼´æÔÚ½ÏΪÏÔÖøµÄÓйØÐÔ¡££¨ÈçÏÂͼ£©

×êÑл¹½øÐÐÁËApoEÇõÍÑéÖ¤£¬Çõͺóµ¼ÖÂÑ×Ö¢¼õÇᡢϸ°ûÕ³¸½Ôö³¤ºÍϸ°û»îÐÔÉý¸ß¡£ÓëNC×éÏà±È£¬ÇõÍ×éÖÐ×ÔÊÉÌå±êÖ¾ÎïLC 3B II/LC 3B Iµ°°×±í°×ÏÔÖø½µµÍ£¬Åú×¢ÆÏÌÑÌÇÓÕµ¼¸ü¸ßµÄ×ÔÊÉˮƽ£¬ÇõÍApoE½µµÍ×ÔÊÉˮƽ¡£
ÍøÂçÒ©Àíѧ£ºÑé֤ʯɼ¼î¼×µÄ¶à°Ðµã×÷ÓÃ
ͨ¹ýÍøÂçÒ©Àíѧ·ÖÎö£¬×êÑÐÈËÔ±½øÒ»²½ÑéÖ¤ÁËʯɼ¼î¼×¿ÉÄÜͨ¹ý°ÐÏòµ÷¿Ø¶à¸öÓëDNÓйصĻùÒòºÍ´úлõè¾¶À´²ûÑï×÷ÓÃ, ²¢ÇÒ¿ÉÄÜͨ¹ý½ÚÔìϸ°ûµòÍö¶øÆð±£»¤×÷Óá£
½áÂÛ£ºÊ¯É¼¼î¼×µÄDZÁ¦Ó뽫À´×êÑз½Ïò
¸Ã×êÑгõ´ÎÌṩÁËʯɼ¼î¼×¶ÔDNÒ½ÖÎ×÷ÓõÄÖ¤¾Ý£¬Åúעʯɼ¼î¼×¿ÉÄÜͨ¹ý°ÐÏòµ÷¿ØApoE£¬³ÉΪһÖÖDZÔÚµÄÔ¤·ÀºÍÒ½ÖÎDNµÄÒ©Îï¡£Ö»¹Ü×êÑлñµÃÁËÁîÈ˹ÄÀøµÄÁ˾֣¬µ«ÈÔÐè½øÒ»²½µÄÁÙ´²ÊÔÑéºÍ´ó¹æÄ£¶à×éѧÊý¾ÝÑéÖ¤À´ÆÀ¹Àʯɼ¼î¼×µÄÁÙ´²Ò½ÖÎDZÄÜ¡£
ÌÇÄò²¡Éö²¡µÄÒ½ÖÎÊÇÒ»¸ö¸´ÔӵĹý³Ì£¬µ«ÕâÏî×êÑÐΪÎÒÃÇÌṩÁËеÄÊӽǺ͵«Ô¸¡£Ëæ×Å×êÑеÄÉî¿Ì£¬ÎÒÃǵȴýʯɼ¼î¼×¿ÉÄܳÉΪÌÇÄò²¡»¼ÕßµÄи£Òô¡£ÈÃÎÒÃÇһ·¹Ø×¢ÕâÒ»ÁìÓòµÄ×îнøÕ¹£¬ÎªÌÇÄò²¡»¼Õß´øÀ´¸ü¶àµÄµ«Ô¸ºÍÑ¡Ôñ¡£
×êÑÐÎļþÆðÔ´£º

ÉêÃ÷£º
1.±¾ÐÂÎÅÖ¼ÔÚ·ÖÏíѧÊõÇ°ÑØ¶¯Ì¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿»ùÓÚѧÊõÖ÷ÕŲÎÔÄ£¬·Ç¸æ°×Óô¦¡£
2.J9¼¯ÍÅÔìÒ©²»ºÏÈκÎÒ©Æ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍÆ¼ö¡£
ÓйØÍƼö